No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
RPG Life Sciences Limited operates as a comprehensive pharmaceutical entity, engaged in the creation, production, and sale of branded drug formulations, generic medicines, and synthetic active pharmaceutical ingredients (APIs) both within India and across global markets. Their portfolio of synthetic APIs spans diverse therapeutic fields, encompassing treatments for conditions such as immunosuppression, psychosis, angina, parasitic infections, seizures, and spasms, among others. The company primarily supplies generic medications for immunosuppressant conditions, alongside a broad range of finished dosage formulations targeting numerous health issues. Its therapeutic reach extends to a vast number of medical areas, including nephrology, rheumatology, oncology, gastroenterology, cardiovascular, orthopedics, respiratory, neurology, urology, diabetes management, dengue fever, nutritional supplements, gynecology, and pediatrics, among many others. Initially established as RPG Pharmaceuticals Limited, the organization rebranded to RPG Life Sciences Limited in February 2008. Founded in 1968, this Mumbai, India-headquartered firm functions as a subsidiary under the Nucleus Life Trust.
www.rpglifesciences.comNo one on the platform currently holds RPGLIFE.BO.
No tracked institution reports a position in RPGLIFE.BO as of their last filing.
No one on the platform has traded RPGLIFE.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 19.8% | 27.9% | 20.4% | — | — | — |
| Rev. Growth % | 8.3% | 13.0% | ||||
| Profit Margin % | 16.3% | 16.9% | 11.7% | |||
| Free Cash Flow Margin % | -0.0% | 6.3% | 4.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $3.5B | +14.7% | $14.94 | $14.94–$14.94 | — | 1 |
| 2028 | $4.2B | +20.8% | $23.68 | $23.68–$23.68 | — | 1 |
| 2029 | $3.7B | -12.2% | $19.61 | $19.61–$19.61 | — | 1 |
| 2030 | $4.1B | +11.7% | $22.69 | $22.69–$22.69 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 7 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-04-27 | $4.46 | $18.08 | +305.4% |
| 2026-01-22 | $3.87 | $13.38 | +245.7% |
| 2025-11-05 | $3.87 | $22.28 | +475.7% |
| 2025-07-25 | $3.87 | $15.90 | +310.9% |
| 2025-04-28 | $4.46 | $70.95 | +1490.8% |
| 2025-01-24 | $3.87 | $21.12 | +445.7% |
| 2024-11-07 | $3.87 | $2.54 | -34.4% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| RPGLIFE.BORPG Life Sciences Limited | $2717.40 | +0.46% | $45.3B | — |
| AARTIDRUGS.BOAarti Drugs Limited | $426.85 | -0.32% | $39.0B | — |
| AARTIDRUGS.NSAarti Drugs Limited | $426.35 | -0.50% | $38.9B | — |
| INNOVACAP.NSInnova Captab Limited | $1140.10 | -0.62% | $65.2B | — |
| ORCHPHARMA.NSOrchid Pharma Limited |
| $987.00 |
| -1.60% |
| $50.1B |
| — |
| SHILPAMED.BOShilpa Medicare Limited | $911.85 | -5.31% | $89.2B | — |
| SPARC.NSSun Pharma Advanced Research Company Limited | $188.00 | -4.09% | $61.0B | — |
Source: Financial Modeling Prep · peers by sector/industry